Edukimi:
Shtator-2000, Fillimi i studimeve per Mjekesi te Pergjithshme prane Fakultetit te “Medicina e Chirurgia” ne “L’Università degli Studi di Roma La Sapienza”
15 Mars-2004 Fitues i te drejtes per “Mjek Frekuentues” prane “Dipartimento di Scienze Cardiovascolari, Respiratorie e Morfologiche” I cattedra di Cardiologia, Policlinico Umberto I, L’Universita degli Studi di Roma La Sapienza.
29 Shtator-2006 Mbarimi i studimeve dhe Diplomimi ne “Mjekesi dhe Kirurgji te pergjithshme” prane l’Università degli Studi di Roma “La Sapienza” Relatore Prof. Carmine Dario Vizza Vleresimi final: 110/110 e lode.
10 Janar-2007 Abilitimi per te ushtruar profesionin e “Mjekut Kirurg” prane ”l’Università degli Studi di Roma “La Sapienza”, me vleresimin final: 270/270-esimi.
17 Prill-2007 I nenshkruar ne “Ordine dei Medici Chirurghi e Odontoiatri della Provincia di Roma dal N° d’ordine 55895”
20/03/2008–03/04/2012 Specializuar në Kardiologji në ”I Scuola di Specializzazione in Cardiologia” pranë “Il Dipartimento di Scienze Cardiovascolari e Respiratorie, Policlinico Umberto I di Roma” me vleresimin final 70/70 e lode.
2011 Fitues i cmimit “Kardiologu i ri” me i mire ne “Regione Lazio”.
22 Nentor 2012-9 Nentor 2015 Kryerja e Doktoraturës në “Fisiopatologia Angio-Cardio-Toracica ed Imaging” cikli i 28, pranë “Dipartimento di Scienze Cardiovascolari e Respiratorie, Policlinico Umberto I Rome” dhe marrjen e titullit “Doktor Shkencash” me vleresimin maksimal.
EKSPERIENCA PROFESIONALE
Nga 2004 deri ne 2013, pranë “Università degli Studi di Roma “La Sapienza”, gjate frekuentimit si “Mjek Frekuentues” dhe gjate periudhes se specializimit ne Kardiologji, u jam dedikuar si aspekteve klinike, ashtu edhe diagnostikimit jo invaziv (TTE, eco-stress, test da sforzo, Holter ECG, Holter i presionit), semi-invaziv (TEE) dhe invaziv ( kateterizm kardiak i djathtë, koronarografi diagnostikuese) të pacientit kardiopatik si eksperiencë e përditshme pune.
Nen-specializim ne degen e Kardiologjise persa i perket “Kardiologjise Intensiviste” per nje periudhe 3-vjecare prane UTIC (Unita di Terapia Intensiva Cardiologica/Coronarica) I Catedra di Cardiologia, Policlinico Umberto I, Rome.
Gjate periudhes 2009-2013 eksperience pune si mjek Kardiolog prane “Casa di Cura Villa Mafalda”, Casa di Cura Villa Margherita” dhe prane “Casa di Cura Villa Stuart, Rome”.
Nga periudha 2004-2013 pjese aktive e “Centro dell’ Ipertensione Arteriosa Polmonare e Forme Associate”, prane “Policlinico Umberto I Rome” si qender referimi ne Itali dhe ne Europe, duke konsiliduar nje eksperience te gjate ne diagnose dhe trajtim te pacientit me “Ipertension Pulmonar” dhe te tjera patologji kardiake te djathta ne pergjithesi.
AKTIVITETI KERKIMOR
Study coordinator per protokollin klinik internazional N° A1481243: “A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20 mg tid or placebo when added to bosentan in the treatment of subjects, aged 18 years and above, with pulmonary arterial hypertension (PAH)”
Study coordinator per protokollin klinik internazional N° A1481244: “A multinational, multicentre, randomized, parallel group, double-blind study to assess the efficacy and safety of 1 mg, 5 mg, 20 mg TID of oral sildenafil in the treatment of subject aged 18 year and over with pulmonary arterial hypertension (PAH)”
Study coordinator per protokollin klinik internazional N° AC-055-302 (SERAPHIN): “A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients whit symptomatic pulmonary arterial hypertension”
Study coordinator per protokollin klinik internazional N° AC-055-303 (SERAPHIN-OL): “Long- term single arm open-label extension study of the SERAPHIN study, to assess the safety and tolerability of ACT-064992 in patients with symptomatic pulmonary arterial hypertension”
Sub-investigator per protokollin klinik internazional N° 11348 (CHEST-1): “Randomized, double-blind, multicenter, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patient with Chronic Thromboembolic Pulmonary hypertension (CTEPH)”
Sub-investigator per protokollin klinik internazional N° 11349 (CHEST-2): “Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patient with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)”
Sub-investigator per protokollin klinik internazional N° 12934 (PATENT-1): “Randomized, double-blind, placebo-controlled, multicentre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)”
Sub-investigator per protokollin klinik internazional N° 12935 (PATENT-2): “Long-term extension, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)”
Study coordinator per protokollin klinik internazional N° A093 (ASCEND-HF): “Double-blind, placebo-controlled, multi center acute study of clinical effectiveness of nesiritide in subjects with decompensated heart failure”
Study coordinator per protokollin klinik internazional N° CK-LX3401 (BALANCE): “Treatment of hyponatriemia based on lixivaptan in NYHA class III/IV cardiac patient evaluation”
Study coordinator per protokollin klinik internazional N° CQTI571A2301 (IMPRES): “A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficay Study”
Study coordinator per protokollin klinik internazional N° RLX.CHF.003 (Pre-RELAX-AHF/RELAX– AHF): “A phase II/III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of relaxin in subjects With Acute Heart Failure”
Sub-investigator per il protocollo clinico internazionale TDE-PH-308 (FREEDOM-C2): “A 16-week, international, multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension”
PUBLIKIME:
Vizza CD, Letizia C, Badagliacca R, Poscia R, Pezzuto B, Gambardella C, Nona A, Papa S, Marcon S, Mancone M, Iacoboni C, Riccieri V, Volterrani M, Fedele F. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. Int J Cardiol. 2012 Jan 18. [Epub ahead of print] Index Pubmed
Vizza CD, Letizia C, Petramala L, Badagliacca R, Poscia R, Zepponi E, Crescenzi E, Nona A, Benedetti G, Ferrante F, Sciomer S, Fedele F. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. Regul Pept. 2008 Nov 29;151(1-3):48-53. Epub 2008 Aug 16. Index Pubmed
Pulmonary arterial dilatation in pulmonary hypertension: prevalence and prognostic relevance.Badagliacca R, Poscia R, Pezzuto B, Papa S, Nona A, Mancone M, Mezzapesa M, Nocioni M, Sciomer S, Valli G, Cedrone N, Fedele F, Vizza CD.Cardiology. 2012;121(2):76-82. doi: 10.1159/000336172. Epub 2012 Mar 15. Index Pubmed.
Right ventricular dyssynchrony in idiopathic pulmonary arterial hipertension: determinants and impact on pump function. Badagliacca R, Poscia R, Pezzuto B, Papa S, Gambardella C, Francone M, Mezzapesa M, Nocioni M, Nona A, Rosati R, Sciomer S, Fedele F, Dario Vizza C. J Heart Lung Transplant. 2015 Mar;34(3):381-9. doi: 10.1016/j.healun.2014.06.010. Epub 2014 Jun 21.Indexed Pubmed.
R. Poscia, C.D. Vizza, R. Badagliacca, A. Nona, C. Gambardella, E. Crescenzi, B. Pezzuto, S. Papa, S. Sciomer, F. Fedele Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing Bosentan. Società Italiana di Cardiologia – 69° Congresso Nazionale (Roma, 13-16 dicembre 2008). Giornale Italiano di Cardiologia 2008; 9 (suppl. 1 al n. 12): C320. Abstract
R. Badagliacca, C.D. Vizza, C. Letizia, R. Poscia, E. Crescenzi, C. Gambardella, A. Nona, S. Papa, B. Pezzuto, S. Sciomer, F. Fedele Predictors of clinical worsening in patients with PAH treated with Bosentan. Società Italiana di Cardiologia – 69° Congresso Nazionale (Roma, 13-16 dicembre 2008). Giornale Italiano di Cardiologia 2008; 9 (suppl. 1 al n. 12): C321 . Abstract
C.D. Vizza, R. Poscia, R. Badagliacca, A. Nona, E. Crescenzi, C. Gambardella, B. Pezzuto, F. Fedele Il trattamento medico dell’ipertensione polmonare. Associazione Italiana Pneumologi Ospedalieri. Compendio – L’ipertensione polmonare: aggiornamenti e novità (dicembre 2008; pagg. 26-31.
C.D. Vizza, R. Badagliacca, M. Francone, R. Poscia, B. Pezzuto, S. Papa, S. Marcon, C. Gambardella, A. Nona and F. Fedele. Impact of RV Remodelling on Survival in PAH Patients: Role of RV Mass/Volume Ratio. Chest 2010; 138:928A Vizza C.D., Badagliacca R., Poscia R. , Nona A., Crescenzi E., Ciuffa M., Ferrante F., Sciomer S., Fedele F. Long term result of medical theraphy in patient with pulmonary arterial hypertension. Atti del X World Congress of echocardiography and Cardiovascular Imaging 19-21-oct 2006 Rome
